Neuren Expands NNZ-2591 Pipeline to Target SYNGAP1-Related Disorder

Neuren Pharmaceuticals (ASX: NEU) has announced the inclusion of SYNGAP1-related disorder (SRD) in its NNZ-2591 neurodevelopmental pipeline, following positive results in a human iPSC-derived neuron model. SRD, caused by mutations in the SYNGAP1 gene, impairs synaptic communication and leads to severe neurological symptoms such as intellectual disability, epilepsy, developmental delays, and autism spectrum disorder. With no approved treatments available, the condition affects approximately 1 in 16,000 individuals. In pre-clinical studies, NNZ-2591 reversed neuronal dysfunction linked to SRD. Neuren is also preparing for a Phase 3 trial of NNZ-2591 in Phelan-McDermid syndrome and has achieved positive Phase 2 results in Pitt Hopkins and Angelman syndromes. Alongside NNZ-2591, Neuren’s approved drug DAYBUE™ (trofinetide) treats Rett syndrome under an exclusive licence to Acadia Pharmaceuticals. The company continues to focus on creating groundbreaking treatments for rare neurological conditions that begin in childhood.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com